Ipsen hands back Parkinson's drug rights to Santhera

French drugmaker Ipsen ($IPN) has a game plan for developing new drugs, and Santhera's ($SANN) Parkinson's disease treatment fipamezole didn't make the cut. Switzerland-based Santhera said that it has regained worldwide rights to the experimental drug from Ipsen and is now looking for a new partner for the program, which is set to enter late-stage studies for treating dyskinesia in Parkinson's patients, Reuters reported. In return for handing back rights to the drug to Santhera for markets outside North America and Japan, Ipsen is expected to get a cut of potential milestones and royalties related to fipamezole. Article

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.